Article
A CYP3A4 phenotype-based dosing algorithm for individualized treatment of irinotecan.
Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Jan 2010
van der Bol Jessica M, Mathijssen Ron H J, Creemers Geert-Jan M, Planting André S Th, Loos Walter J, Wiemer Erik A C, Friberg Lena E, Verweij Jaap, Sparreboom Alex, de Jong Floris A
Abstract excerpt
PURPOSE: Irinotecan, the prodrug of SN-38, is extensively metabolized by cytochrome P450-3A4 (CYP3A4). A randomized trial was done to assess the utility of an algorithm for individualized irinotecan dose calculation based on a priori CYP3A4 activity measurements by the midazolam clearance test. E...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.